Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;49(11):978-987.
doi: 10.1111/cup.14299. Epub 2022 Aug 23.

Lichen-planus-pemphigoides-like reaction to PD-1 checkpoint blockade

Margaret Wat  1 , Nicholas K Mollanazar  2 , Christoph T Ellebrecht  2 , Amy Forrestel  2 , Rosalie Elenitsas  2 , Emily Y Chu  2
Affiliations
Review

Lichen-planus-pemphigoides-like reaction to PD-1 checkpoint blockade

Margaret Wat et al. J Cutan Pathol. 2022 Nov.

Abstract

Background: Programmed cell death protein (PD-1) and programmed death-ligand 1 (PD-L1) inhibition checkpoint blockade leads to various cutaneous adverse reactions, including bullous pemphigoid and lichen-planus-like reactions. However, lichen planus pemphigoides (LPP), manifesting histopathologic features of both lichen planus and bullous pemphigoid, has more rarely been associated with immunotherapy.

Methods: The clinical and histopathologic findings of three patients were examined, and a review of cases of LPP and bullous lichen planus secondary to PD-1 inhibitor therapy was performed.

Results: Three patients (two with advanced non-small-cell lung adenocarcinoma and the third with metastatic breast cancer) presented with both lichenoid eruptions and bullae. Biopsy of the lesions revealed lichenoid tissue reactions in all three patients. Together with the histopathologic findings, direct immunofluorescence (DIF) showing linear C3 and IgG deposition and positive enzyme-linked immunosorbent assay (ELISA) showing BP180 positivity supported a diagnosis of LPP in two patients. The third patient in our series also showed confirmatory ELISA testing supporting LPP.

Conclusions: Lichen planus pemphigoides is a distinct cutaneous toxicity to checkpoint inhibitor therapy illustrates a possible pathogenic mechanism and the importance of dermatopathology recognition to render an accurate diagnosis.

Keywords: PD-1 inhibitor; immune-related adverse events; lichen planus pemphigoides; pembrolizumab.

PubMed Disclaimer

References

REFERENCES

    1. Coscarart A, Martel J, Lee MP, Wang AR. Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus. J Cutan Pathol. 2020;47(3):275-279. doi:10.1111/cup.13587
    1. Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255-1268. doi:10.1016/j.jaad.2020.03.132
    1. Chan L, Hwang SJE, Byth K, et al. Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events. J Am Acad Dermatol. 2020;82(2):311-316. doi:10.1016/j.jaad.2019.06.035
    1. Gawkrodger DJ, Stavropoulos PG, McLaren KM, Buxton PK. Bullous lichen planus and lichen planus pemphigoides--clinico-pathological comparisons. Clin Exp Dermatol. 1989;14(2):150-153. doi:10.1111/j.1365-2230.1989.tb00914.x
    1. Min Lee CK, Li S, Tran DC, et al. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study. J Am Acad Dermatol. 2018;79(6):1047-1052. doi:10.1016/j.jaad.2018.05.035

MeSH terms